FEDERAL COURT OF AUSTRALIA
InterPharma Pty Ltd v Commissioner of Patents [2008] FCA 1422
INTERPHARMA PTY LTD v THE COMMISSIONER OF PATENTS and ELI LILLY & COMPANY; ELI LILLY & COMPANY and ELI LILLY AUSTRALIA PTY LTD; INTERPHARMA PTY LTD
VID 160 OF 2008
SUNDBERG J
16 SEPTEMBER 2008
MELBOURNE
IN THE FEDERAL COURT OF AUSTRALIA
VICTORIA DISTRICT REGISTRY
VID 160 OF 2008
BETWEEN:
INTERPHARMA PTY LTD
ApplicantELI LILLY & COMPANY
First Cross-ClaimantELI LILLY AUSTRALIA PTY LTD
Second Cross-ClaimantAND:
THE COMMISSIONER OF PATENTS
First RespondentELI LILLY & COMPANY
Second RespondentINTERPHARMA PTY LTD
Cross-Respondent
JUDGE:
SUNDBERG J
DATE:
16 SEPTEMBER 2008
PLACE:
MELBOURNE
REASONS FOR JUDGMENT
On 28 July 2008 I made a confidentiality order under which disclosure of confidential information belonging to the applicant (InterPharma) was limited to the second respondent’s Australian lawyers (including support and administrative staff employed by them), independent experts nominated by the second respondent, and other persons to whom InterPharma consents in writing.
The second respondent and the second cross‑claimant (together Lilly) seek to have two in‑house lawyers, Ms McGraw and Mr Caltrider, brought within the confidentiality regime.
No question arises as to the confidentiality of the relevant documents for the purposes of the present application.
Ms McGraw is Patent Counsel for Lilly. She has primary responsibility for Lilly’s gemcitabine litigation internationally (including in Australia, Canada, the United States, the United Kingdom and China). She is a lawyer and a patent attorney. Her role is purely legal, and she reports to Lilly’s General Counsel. She has no role in prosecuting patents for Lilly, in decision making as to the price or other terms on which gemcitabine is sold, or in developing or commercialising new products, except to provide limited legal advice concerning intellectual property.
Ms McGraw is the source of Lilly’s instructions to its Australian solicitors in this proceeding. She has been involved in gemcitabine patent litigation for Lilly for six years. She has scientific training enabling her to understand technical information relevant to the issues. She is of the view that in order to provide Lilly’s Australian solicitors with proper instructions, including as to expert evidence and litigation strategy generally, she requires access to the technical information relating to allegedly infringing products.
Ms McGraw has been included within confidentiality regimes applicable in gemcitabine litigation in at least four other jurisdictions.
Ms McGraw says she is aware of her legal and ethical obligations in relation to confidential documents and secures them appropriately. I refer to the security safeguards at [11] and [12] below. She is prepared to give a confidentiality undertaking as ordered by the Court.
Mr Caltrider is Lilly’s Deputy General Patent Counsel. He is Ms McGraw’s manager. He is a member of the American Bar Association and is admitted to practice before various State and Federal Courts in the United States. He has oversight and management of all aspects of Lilly’s international patent practice and its international intellectual property groups. His role is purely legal and not commercial.
Mr…
Keep reading for free
Create a free CaseChat account to read Interpharma Pty Ltd v Commissioner of Patents and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2008] FCA 1422
- Decision Date
CaseChat Overview and Summary
The court examined the roles and responsibilities of Ms McGraw and Mr Caltrider, both of whom held senior positions in Eli Lilly's legal department and had significant involvement in international patent litigation. Ms McGraw, as Patent Counsel, had primary responsibility for gemcitabine litigation internationally and had been involved in such litigation for six years. Mr Caltrider, as Deputy General Patent Counsel, managed all aspects of Eli Lilly's international patent practice. Both lawyers were considered essential for providing proper legal advice and instructions to Eli Lilly's Australian solicitors. The court also noted the stringent security measures Lilly had in place for handling confidential documents, including a password-protected electronic storage system and a policy requiring the appropriate protection of confidential information. The court concluded that the risk of prejudice to InterPharma and the third parties was slight given the professional attributes and background of Ms McGraw and Mr Caltrider, their legal ethical obligations, and the existing safeguards.
The court decided that Ms McGraw and Mr Caltrider should be included in the confidentiality regime, subject to certain adjustments. The requirement for the documents to be inspected in Australia was deemed unnecessarily burdensome, given their location and the nature of their work. The restriction on making copies was considered too restrictive, and the existing provision in the confidentiality regime was deemed appropriate. The requirement for Lilly to provide security or compensation for any wrongful disclosure was already covered by the existing regime. The need for Lilly to execute direct confidentiality agreements was deemed unnecessary. The court directed the parties to confer on the final form of the document incorporating these adjustments and to submit it to the court's Associate for further action.
Background
Background to the litigation
The case came before the Federal Court of Australia in the Victoria District Registry. On 28 July 2008, a confidentiality order was made under which disclosure of confidential information belonging to InterPharma was limited to specific parties, including Lilly’s Australian lawyers, independent experts, and others to whom InterPharma consents in writing. This application followed, where Lilly sought to include Ms McGraw and Mr Caltrider within the confidentiality regime. The matter was heard on 12 September 2008, and judgment was delivered by Sundberg J on 16 September 2008.
Decision
Reasons for decision
1. Whether Ms McGraw and Mr Caltrider should be included within the confidentiality regime and if so, under what conditions.
2. Whether the proposed safeguards suggested by InterPharma and the third parties are necessary or appropriate.
Held
1. The Court held that Ms McGraw and Mr Caltrider should be included within the confidentiality regime, subject to certain conditions.
2. The Court held that the proposed safeguards suggested by InterPharma and the third parties were not all necessary or appropriate.
Ratio Decidendi
Legal Principle Established
Established by: SUNDBERG J
The Court considered the need for Ms McGraw and Mr Caltrider to access confidential information to provide proper instructions to Lilly's Australian solicitors and the professional attributes and background of Ms McGraw and Mr Caltrider. It found that their roles were purely legal and they were not involved in competitive decision making. The Court also took into account the safeguards proposed by Lilly, including the security system for confidential documents and the employment policies requiring appropriate protection of confidential information. The Court concluded that the risk of prejudice to InterPharma and the third parties was slight. The Court then considered the proposed safeguards suggested by InterPharma and the third parties. It found that some of the requirements were unnecessarily burdensome or too restrictive, such as the requirement for personal inspection in Australia and the prohibition of making any copies of the confidential information. The Court also found that the requirement for Lilly to execute direct confidentiality agreements was unnecessary in view of the existing liability clause. The Court considered the proposed confidentiality regime put forward by Lilly to be in an appropriate form, subject to certain adjustments.